- BGI Genomics Announces Pricing of Initial Public Offering
- BGI Launches the Latest Desktop Sequencer BGISEQ-50
- International Science Community Welcomes China National GeneBank Opening
- BGI and Clearbridge BioMedics Partner to Develop China CTC Liquid Biopsy Market towards Precision Medicine
- The international Sc2.0 Project is on track to build the world’s first synthetic yeast genome
- Avian-specific conserved genomic elements play important regulatory roles in the macroevolution of avian-specific features
- The Evolution of Chronic Lymphocytic Leukemia Revealed
- BGI involved in publication of the first seahorse genome in Nature
- Leading Health Organizations in Canada and China Teaming up to Accelerate Precision Medicine
- World’s largest genomic organisation to collaborate with leading Queensland researchers
- Ranomics Partners with BGI to Classify Variants of Unknown Significance
- BGI and UW collaborate on precision medicine development
- Chinese innovation : BGI’s code for success
- Prof. Huanming Yang to Receive Membership from Royal Danish Academy of Sciences and Letters
- UW, Chinese genomics group forge new partnership to advance biomedical research
- Mapping more genomes will create a healthcare 'big data revolution'
Tel: +86-755-36307212Email: firstname.lastname@example.org
Cantanhede, Portugal, and Shenzhen, China, September 30, 2013 - China's genomics powerhouse BGI and Portugal-based start-up Coimbra Genomics today announced the initiation of a joint project to unravel the genetic basis of gastric cancer. With an initial budget of over $900k, the project will be one of the first large-scale genomic studies this field, and will involve experts from the IPATIMUP, a leading cancer research institute based in Oporto, Portugal, with a particularly strong track-record on gastric cancer.
“This collaboration forges new ties between BGI and Coimbra Genomics to share and exchange knowledge and research ideas. We expect our join efforts can yield more breakthroughs for better conquering stomach cancer.” said Yuan Liu, Europe business development director of BGI Tech, one of BGI’s affiliates. “We strongly encourage more European researchers to join us in our efforts to further accelerate the genomic applications in human health, agriculture, bio-energy as well as other innovative research.”
Coimbra Genomics CEO and co-founder Nuno Arantes-Oliveira added, “We are delighted to engage with BGI in this pioneering project and hope it becomes a great example of Sino-EU research collaboration to produce excellent science and, above all, to pave the way for new diagnostic and therapeutic solutions for serious diseases.”
With almost one million new cases every year, gastric cancer is the second most common cause of cancer death after lung cancer. The disease is particularly common in East and Southeast Asia, as well as in Latin America and parts of Eastern and Southern Europe. The genetic basis of the disease is still poorly understood; early diagnosis is difficult and there is great need for effective treatments.
About Coimbra Genomics
Coimbra Genomics S.A. was launched in 2013 to develop clinical decision support systems based on patients' whole genome sequencing. The company also carries out genomic studies in areas of particular medical need. Benefiting from close connections to the medical community, Coimbra Genomics raised a first, seed round of funding from two venture capital funds in July 2013. The company's founders include software firm Critical Software, the Biocant Park, and several individual scientists and entrepreneurs.
Ms. Catherine Wen Gao
Marketing Communication Manager
BGI Tech Europe
Tel: +45 81730147